Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Cancer J. 2013 Jul-Aug;19(4):10.1097/PPO.0b013e31829d74b4. doi: 10.1097/PPO.0b013e31829d74b4

Figure 2.

Figure 2

Schema showing the randomization employed in the phase III assessment of AGS-003. AGS-003 is delivered every six weeks for a total of 48 weeks. Patients with stable disease or better at 48 weeks may continue AGS-003 injections quarterly until progressive disease is noted.